McCarter et al. RA patients intiating ICI. 46% risk of flare, happens quickly (27% in first 28 days) and then plateaus. Seropositive higher risk HR 1.95. No difference in mortality. @RheumNow #ACR22 Abstr#1667 https://t.co/o9SKdNAYcE https://t.co/FmN89LAggG

Ab1671 #ACR22 Cervical Cancer screening in SLE 106 SLE patients, mean age 40. Only 3.7% w HPV vax! 24% abnml PAP, 30% HPV infection HPV highest in 21-26 yo (83%) vs 27-45 (35%) ASCUS 50% HPV+, 1 pt squamous cell ca Recs: HPV Vax💉, test HPV as high positivity @RheumNow @KDAO2011 https://t.co/nHlvGVVm40

Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks. @RheumNow #ACR22 #LateBreaking

Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12 Also greater improvement of CDAI in both treated grps TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg https://t.co/QtclWIWAw9 Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt

Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h

Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE than those in lowest tertile. Exacerbated by high BMI. @RheumNow #ACR22 Abstr#1634 https://t.co/T4Bx59VJPX https://t.co/oWaj9QbzgY

Important late breaker re:barriers to MTX post Roe decision 6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists This number should be 0%!! #ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25

Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis #ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC